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Introduction
In the literature coexistence of ovarian and endo-
metrial cancers is the most common in synchronous 
genital tract cancers. Bilateral ovarian tumours are ex-
tremely rare, and therefore limited data are available for 
the management of these cases. 
Epithelial ovarian cancer (EOC) is the most common 
in ovarian cancers and accounts for nearly 90% of all [1]. 
The majority of cases are diagnosed at an advanced 
stage and frequently with bilateral ovarian and perito-
neal invasion. Ovarian malignant mixed Müllerian tu-
mours (MMMT) are very rare and account for only 1-4% 
of ovarian cancers [2]. 
Both EOC and ovarian MMMT usually present with 
an adnexal mass and advanced stage disease [3]. Also 
both have similar management including debulking 
surgery and concomitant chemotherapy. Cytoreduc-
tive surgery is the initial approach for both in advanced 
stages [4, 5]. Platin-based chemotherapy is standard 
for EOC in first-line therapy [6] and also has a positive 
prognostic effect in MMMT [7]. 
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Abstract
Synchronous ovarian tumours are rare. Management of these patients can differ from that of patients with 
uniform tumours. We present a case of synchronous epithelial ovarian cancer and malignant mixed Müllerian 
tumour in different ovaries, its follow-up and management until death. To our knowledge this is the second case 
in the English literature to date.
A  61-year-old woman with bilateral adnexal masses underwent complete debulking surgery for ovarian 
cancer. The final pathology was reported as malignant mixed Müllerian tumour in the right ovary with intact 
borders and stage 2 grade 3 serous carcinoma in the left ovary. She had a 17-month disease-free interval after 
6 cycles of paclitaxel and carboplatin. Recurrence of malignant mixed Müllerian tumour was reported in the pa-
thology after secondary debulking including a partial ileal resection. After 6 cycles of gemcitabine and cisplatin 
she had a widespread recurrence in the thorax and abdomen. The patient died of disease recurrence at the 25th 
month after diagnosis.
Coexistence of serous and malignant mixed Müllerian tumour in different ovaries is very rare. The main 
treatment is complete cytoreduction followed with chemotherapy. Platinum-taxane based chemotherapy re-
sulted in an acceptable disease-free interval in our case, but it is not standard yet. A management protocol may 
be developed with the increasing number of similar cases in the literature.
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We present a case with serous type EOC and MMMT, 
diagnosed at two different ovaries, and the issue is dis-
cussed together with the literature.
Case presentation
A 61-year-old postmenopausal woman was referred 
to our clinic with a pelvic mass. Her primary symptom 
was pelvic pain. Bilateral adnexal masses and pelvic 
fluid collection were determined with pelvic examina-
tion and transvaginal ultrasonography. In laboratory 
findings, Ca-125 concentration was 350.7 U/ml. Thorax 
and abdominal computed tomography also indicated 
an ovarian neoplasm limited to the pelvis.
In the light of these findings the patient was sub-
jected to laparotomy with a midline incision. Hysterec-
tomy and bilateral salpingoophorectomy material was 
sent for frozen section and reported as a malign neo-
plasm of the ovary. Staging surgery was performed for 
ovarian cancer (Fig. 1). The final pathology was reported 
as MMMT (carcinoma component serous + endome-
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trioid and sarcomatous component with heterologous 
elements of chondrosarcoma and rhabdomyosarcoma) 
in the right ovary with intact borders and grade 3 se-
rous carcinoma in the left ovary, with a tumour on the 
surface (Figs. 2 and 3). Abdominal washing was tumour 
positive. None of 49 lymph nodes was involved but ne-
crotic carcinosarcomatous tumour nodules were seen 
in the left external and obturator region. There were 
no complications in the postoperative period and the 
patient was discharged on the 7th day. She was dis-
cussed in our gynaecology oncology unit and 6 cycles 
of paclitaxel + carboplatin every 21 days treatment was 
planned. Her treatment was performed regularly with 
no adverse affects of chemotherapy and finished in the 
4th month after surgery. In the follow-up, she had a re-
currence at the 17th month in April 2014 and was sub-
jected to debulking surgery with colonic resection. The 
final pathology was reported as recurrence of MMMT. 
Gemcitabine + cisplatin chemotherapy every 21 days 
was planned again. After regular treatment finished at 
4 months she had widespread disease in two months 
and despite intensive care she died in the 25th month 
after the first diagnosis of the disease.
Discussion
EOCs are the most common malignancies of the 
ovary. Serous histology is the most common type and is 
generally caught at advanced stages and bilateral ovar-
ian involvement.
Otherwise MMMT is a  rare ovarian tumour which 
occurs from pluripotent mesenchymal cells of the coe-
lomic epithelium. These are differentiated carcinomas 
of the ovary and are thought to occur from pre-existing 
carcinomas. 
Bilateral ovarian synchronous tumours are very 
rare. Bernárdez Zapata et al. presented a 49-year-old pa-
tient with two different epithelial cancers in two ovaries: 
a clear cell carcinoma in the left ovary, and a moderately 
differentiated endometrioid carcinoma in the right one [8]. 
Semczuk et al. reported a 73 year-old patient with syn-
chronous granulosa cell tumour and a fibroma [9]. 
Epithelial and sarcomatous synchronous neoplasms 
have different origins and are more uncommon. Only 
one case similar to ours has been described before – 
a  58-year-old woman with bilateral ovarian synchro-
nous malignant tumours [10]. In 2008, ovarian cancer 
with a mesenteric MMMT was presented by Ma et al. [11]. 
Arora et al. reported a case of MMMT of the broad liga-
ment in association with uterine endometrioid adeno-
carcinoma along with papillary serous carcinoma of the 
ovary [12]. Tae Yeon Lee et al. presented a 57-year-old 
patient with MMMT that originated from both the uter-
us and ovary [13]. 
EOC and MMMT are usually diagnosed at advanced 
stages and have a poor prognosis. Stage and optimal 
cytoreductive surgery are important prognostic factors 
for both. These cancers have highly aggressive natures 
Fig. 1. TAH + BSO gross view. Normal uterus. Right ovary has 
multilobulated solid and haemorrhagic areas, and left ovary 
has a yellow-grey solid + cystic pattern
Fig. 2. Histopathological image of left ovary. Serous adenocarcinoma (H&E ×10 original magnification and inset ×20 original 
magnification)
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and in management after debulking and staging sur-
gery, chemotherapy is needed. Platinum-taxane based 
chemotherapy is the first choice for EOC. Multiple ad-
juvant therapies for MMMT have been reported in the 
literature including doxorubicin, cisplatin, dacarbazine, 
paclitaxel, carboplatin and ifosfamide [14-16]. In terms 
of these approaches platinum-taxane based adjuvant 
therapy may be a good option for synchronised MMMT 
and EOC. 
Conclusions 
We have reported the case of a patient with serous 
adenocarcinoma and MMMT in different ovaries from 
the first diagnosis until death. MMMT was stage 2b and 
serous cancer was stage 1c. The patient was treated 
with paclitaxel and carboplatin chemotherapy, which 
is standard for ovarian cancer and well accepted for 
MMMT treatment. After treatment she had a 17-month 
disease-free survival. 
Today there is an increasing trend in synchronous 
tumour cases. There have been reports with simultane-
ous occurrence of two different tumours at different 
sites in the female genital tract. These may have more 
complicated management or treatment. We believe 
Fig. 3. Histopathological image of right ovary. Epithelial ade-
nocarcinoma component, rhabdomyosarcomatous and chon-
drosarcomatous heterologous elements of malignant mixed 
Müllerian tumours (H&E ×10 original magnification)
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that platinum-taxane based chemotherapy may be 
a  good choice in patients with synchronous EOC and 
MMMT after optimal cytoreduction. Therefore, sharing 
more knowledge and more cases will be advantageous. 
Here we have reported a  case of serous tumour and 
MMMT in two ovaries with their management to con-
tribute to the literature.
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